Tandospirone Citrate in the Treatment of Patients With Generalized Anxiety Disorder: a Multi-center, Randomized, Usual Dose-controlled Trial

Trial Profile

Tandospirone Citrate in the Treatment of Patients With Generalized Anxiety Disorder: a Multi-center, Randomized, Usual Dose-controlled Trial

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 18 Oct 2016

At a glance

  • Drugs Tandospirone (Primary)
  • Indications Generalised anxiety disorder
  • Focus Therapeutic Use
  • Acronyms TACGAD
  • Sponsors Sumitomo Dainippon Pharma
  • Most Recent Events

    • 13 Oct 2016 Planned End Date changed from 1 Oct 2017 to 1 Dec 2017.
    • 13 Oct 2016 Planned primary completion date changed from 1 Aug 2016 to 1 Dec 2016.
    • 20 Nov 2015 Planned End Date changed from 1 Oct 2015 to 1 Oct 2017 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top